Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives

Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives

Several elements highlight the importance of the mechanistic target of rapamycin (mTOR) in the biology of renal cell carcinoma (RCC). mTOR signaling pathway is indeed frequently activated in RCC, inducing cancer cell proliferation and survival. In addition, mTOR promotes tumor angiogenesis and regul...

Full description

Bibliographic Details
Main Authors:	Seraina Faes, Nicolas Demartines, Olivier Dormond
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-03-01
Series:	Frontiers in Cell and Developmental Biology
Subjects:	mTOR rapalogs renal cell carcinoma HIF-α angiogenesis
Online Access:	https://www.frontiersin.org/articles/10.3389/fcell.2021.636037/full

Similar Items

Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy
by: Seraina Faes, et al.
Published: (2017-11-01)

Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives
by: Olivier Dormond, et al.
Published: (2011-05-01)

Combining mTOR Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment
by: Alexandre el Hage, et al.
Published: (2021-03-01)

In vitro delivery of mTOR inhibitors by kidney-targeted micelles for autosomal dominant polycystic kidney disease
by: Alysia Cox, et al.
Published: (2023-08-01)

A Stable Micellar Formulation of RAD001 for Intracerebroventricular Delivery and the Treatment of Alzheimer’s Disease and Other Neurological Disorders
by: Laura Gianessi, et al.
Published: (2023-12-01)

Kinase Inhibitors and Ovarian Cancer
by: Periklis Katopodis, et al.
Published: (2019-09-01)

Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting
by: James T. Murray, et al.
Published: (2018-05-01)

Blocking Mammalian Target of Rapamycin (mTOR) Attenuates HIF-1α Pathways Engaged-Vascular Endothelial Growth Factor (VEGF) in Diabetic Retinopathy
by: Jie Wei, et al.
Published: (2016-12-01)

The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside
by: Yimei Feng, et al.
Published: (2021-01-01)

AI-Predicted mTOR Inhibitor Reduces Cancer Cell Proliferation and Extends the Lifespan of <i>C. elegans</i>
by: Tinka Vidovic, et al.
Published: (2023-04-01)

Oxymatrine combined with rapamycin to attenuate acute cardiac allograft rejection
by: Xu Lan, et al.
Published: (2024-04-01)

Dual Roles of the AMP-Activated Protein Kinase Pathway in Angiogenesis
by: Yuanjun Li, et al.
Published: (2019-07-01)

Mechanistic target of rapamycin (mTOR): a potential new therapeutic target for rheumatoid arthritis
by: Fen Zhang, et al.
Published: (2023-10-01)

Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways
by: Liu QJ, et al.
Published: (2016-02-01)

Mammalian target of rapamycin inhibitors: A paradigm shift in current immunosuppression protocols
by: Indranil Ghosh, et al.
Published: (2016-01-01)

Searching for the real function of mTOR signaling in the regulation of PD-L1 expression
by: Shi-Yong Sun
Published: (2020-12-01)

Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
by: Won Seop Kim
Published: (2011-06-01)

Mechanistic target of rapamycin signaling in human nervous system development and disease
by: Marie Girodengo, et al.
Published: (2022-09-01)

Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α
by: Olga‐Demetra Biziotis, et al.
Published: (2023-11-01)

Gefitinib Results in Robust Host-Directed Immunity Against Salmonella Infection Through Proteo-Metabolomic Reprogramming
by: Srikanth Sadhu, et al.
Published: (2021-03-01)

AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug Sitagliptin for the Management of Hepatocellular Carcinoma
by: Eslam E. Abd El-Fattah, et al.
Published: (2022-01-01)

Discovery of small molecule mechanistic target of rapamycin inhibitors as anti-aging and anti-cancer therapeutics
by: Zofia Chrienova, et al.
Published: (2022-12-01)

SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers
by: Sarah Jannier, et al.
Published: (2020-10-01)

Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy
by: Wei Zhao, et al.
Published: (2023-06-01)

Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
by: Blaser Benjamin, et al.
Published: (2012-03-01)

Enhanced activation of mechanistic target of rapamycin complex 1 signaling in eruptive xanthomas
by: Yan Huang, BS, et al.
Published: (2023-12-01)

UCP2 promotes NSCLC proliferation and glycolysis via the mTOR/HIF‐1α signaling
by: Cailu Song, et al.
Published: (2024-02-01)

Metformin ameliorates liver fibrosis induced by congestive hepatopathy via the mTOR/HIF-1α signaling pathway
by: Jing Yang, et al.
Published: (2023-11-01)

2-Oxonanonoidal Antibiotic Actinolactomycin Inhibits Cancer Progression by Suppressing HIF-1α
by: Jiadong Cheng, et al.
Published: (2019-05-01)

The role of curcumin in disruption of HIF-1α accumulation to alleviate adipose fibrosis via AMPK-mediated mTOR pathway in high-fat diet fed mice
by: Zhixia Qiu, et al.
Published: (2017-06-01)

CCI-779 Inhibits Rhabdomyosarcoma Xenograft Growth by an Antiangiogenic Mechanism Linked to the Targeting of mTOR/Hif-1α/VEGF Signaling
by: Xiaolin Wan, et al.
Published: (2006-05-01)

The Impairments of α-Synuclein and Mechanistic Target of Rapamycin in Rotenone-Induced SH-SY5Y Cells and Mice Model of Parkinson’s Disease
by: Mahesh Ramalingam, et al.
Published: (2019-09-01)

α-Enolase Lies Downstream of mTOR/HIF1α and Promotes Thyroid Carcinoma Progression by Regulating CST1
by: Yang Liu, et al.
Published: (2021-04-01)

PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis
by: Silviu Constantin Badoiu, et al.
Published: (2023-05-01)

Effect of mechanistic/mammalian target of rapamycin complex 1 on mitochondrial dynamics during skeletal muscle hypertrophy
by: Kazuki Uemichi, et al.
Published: (2021-03-01)

Recent advances and limitations of mTOR inhibitors in the treatment of cancer
by: Eunus S. Ali, et al.
Published: (2022-09-01)

Lysophosphatidic Acid Induces Aerobic Glycolysis, Lipogenesis, and Increased Amino Acid Uptake in BV-2 Microglia
by: Lisha Joshi, et al.
Published: (2021-02-01)

Antitumor effects of low‐dose tipifarnib on the mTOR signaling pathway and reactive oxygen species production in HIF‐1α‐expressing gastric cancer cells
by: Noriyuki Egawa, et al.
Published: (2021-05-01)

Epigenetic downregulation of STAT6 increases HIF-1α expression via mTOR/S6K/S6, leading to enhanced hypoxic viability of glioma cells
by: Soo Jung Park, et al.
Published: (2019-09-01)

Triclosan-induced glycolysis drives inflammatory activation in microglia via the Akt/mTOR/HIF 1α signaling pathway
by: Jieyu Liu, et al.
Published: (2021-11-01)